145 related articles for article (PubMed ID: 7831996)
1. D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects.
Scherer J; Tatsch K; Schwarz J; Oertel WH; Konjarczyk M; Albus M
Acta Psychiatr Scand; 1994 Oct; 90(4):266-8. PubMed ID: 7831996
[TBL] [Abstract][Full Text] [Related]
2. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
[TBL] [Abstract][Full Text] [Related]
3. [123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects.
Schlösser R; Schlegel S; Hiemke C; Nickel O; Bockisch A; Rao ML; Hahn K
Psychiatry Res; 1997 Sep; 75(2):103-14. PubMed ID: 9351492
[TBL] [Abstract][Full Text] [Related]
4. D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects.
Broich K; Grünwald F; Kasper S; Klemm E; Biersack HJ; Möller HJ
Pharmacopsychiatry; 1998 Sep; 31(5):159-62. PubMed ID: 9832346
[TBL] [Abstract][Full Text] [Related]
5. D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment.
Schröder J; Silvestri S; Bubeck B; Karr M; Demisch S; Scherrer S; Geider FJ; Sauer H
Biol Psychiatry; 1998 May; 43(9):660-5. PubMed ID: 9582999
[TBL] [Abstract][Full Text] [Related]
6. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.
Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R
Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.
Farde L; Nordström AL; Wiesel FA; Pauli S; Halldin C; Sedvall G
Arch Gen Psychiatry; 1992 Jul; 49(7):538-44. PubMed ID: 1352677
[TBL] [Abstract][Full Text] [Related]
8. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
Tauscher J; Küfferle B; Asenbaum S; Fischer P; Pezawas L; Barnas C; Tauscher-Wisniewski S; Brücke T; Kasper S
Psychopharmacology (Berl); 1999 Jan; 141(2):175-81. PubMed ID: 9952042
[TBL] [Abstract][Full Text] [Related]
9. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
Knable MB; Heinz A; Raedler T; Weinberger DR
Psychiatry Res; 1997 Sep; 75(2):91-101. PubMed ID: 9351491
[TBL] [Abstract][Full Text] [Related]
10. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
[TBL] [Abstract][Full Text] [Related]
11. Implications of brain imaging for the management of schizophrenia.
Nyberg S; Nilsson U; Okubo Y; Halldin C; Farde L
Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S15-20. PubMed ID: 9690965
[TBL] [Abstract][Full Text] [Related]
12. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
[TBL] [Abstract][Full Text] [Related]
13. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol.
Tauscher J; Küfferle B; Asenbaum S; Tauscher-Wisniewski S; Kasper S
Psychopharmacology (Berl); 2002 Jun; 162(1):42-9. PubMed ID: 12107616
[TBL] [Abstract][Full Text] [Related]
14. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol.
Küfferle B; Tauscher J; Asenbaum S; Vesely C; Podreka I; Brücke T; Kasper S
Psychopharmacology (Berl); 1997 Oct; 133(4):323-8. PubMed ID: 9372530
[TBL] [Abstract][Full Text] [Related]
15. Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics.
Scherer J; Tatsch K; Schwarz J; Oertel W; Kirsch MC; Albus M
Biol Psychiatry; 1994 Nov; 36(9):627-9. PubMed ID: 7833430
[No Abstract] [Full Text] [Related]
16. Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone.
Küfferle B; Brücke T; Topitz-Schratzberger A; Tauscher J; Gössler R; Vesely C; Asenbaum S; Podreka I; Kasper S
Psychiatry Res; 1996 Nov; 68(1):23-30. PubMed ID: 9027930
[TBL] [Abstract][Full Text] [Related]
17. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.
Jauss M; Krack P; Franz M; Klett R; Bauer R; Gallhofer B; Dorndorf W
Mov Disord; 1996 Nov; 11(6):726-8. PubMed ID: 8914102
[TBL] [Abstract][Full Text] [Related]
18. Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients.
Pickar D; Su TP; Weinberger DR; Coppola R; Malhotra AK; Knable MB; Lee KS; Gorey J; Bartko JJ; Breier A; Hsiao J
Am J Psychiatry; 1996 Dec; 153(12):1571-8. PubMed ID: 8942453
[TBL] [Abstract][Full Text] [Related]
19. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study.
Kasper S; Tauscher J; Küfferle B; Barnas C; Hesselmann B; Asenbaum S; Podreka I; Brücke T
Psychopharmacology (Berl); 1998 Apr; 136(4):367-73. PubMed ID: 9600582
[TBL] [Abstract][Full Text] [Related]
20. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.
Tuppurainen H; Kuikka JT; Viinamäki H; Husso M; Tiihonen J
Psychiatry Clin Neurosci; 2009 Aug; 63(4):529-37. PubMed ID: 19496999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
